C.R.S. Section 18-18-203
Schedule I


(1)

A substance shall be added to schedule I by the general assembly when:

(a)

The substance has high potential for abuse;

(b)

The substance has no currently accepted medical use in treatment in the United States; and

(c)

The substance lacks accepted safety for use under medical supervision.

(2)

Unless specifically excepted by Colorado or federal law or Colorado or federal regulation or more specifically included in another schedule, the following controlled substances are listed in schedule I:

(a)

Any of the following synthetic opiates, including any isomers, esters, ethers, salts, and salts of isomers, esters, and ethers of them that are theoretically possible within the specific chemical designation:

(I)

Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl ] -N- phenylacetamide);

(II)

Acetylmethadol;

(III)

Allylprodine;

(IV)

Alphacetylmethadol;

(V)

Alphameprodine;

(VI)

Alphamethadol;

(VII)

Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)- 4-(N-propanilido) piperidine);

(VIII)

Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-4-piperidinyl]-N-phenylpropanamide);

(IX)

Benzethidine;

(X)

Betacetylmethadol;

(XI)

Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-phenylpropanamide);

(XII)

Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl-] N-phenylpropanamide);

(XIII)

Betameprodine;

(XIV)

Betamethadol;

(XV)

Betaprodine;

(XVI)

Clonitazene;

(XVII)

Dextromoramide;

(XVIII)

Diampromide;

(XIX)

Diethylthiambutene;

(XX)

Difenoxin;

(XXI)

Dimenoxadol;

(XXII)

Dimepheptanol;

(XXIII)

Dimethylthiambutene;

(XXIV)

Dioxaphetyl butyrate;

(XXV)

Dipipanone;

(XXVI)

Ethylmethylthiambutene;

(XXVII)

Etonitazene;

(XXVIII)

Etoxeridine;

(XXIX)

Furethidine;

(XXX)

Hydroxypethidine;

(XXXI)

Ketobemidone;

(XXXII)

Levomoramide;

(XXXIII)

Levophenacylmorphan;

(XXXIV)

3-methylfentanyl (N-[3-methyl-1-(2- phenylethyl)-4-piperidyl]-N-phenylpropanamide);

(XXXV)

3-methylthiofentanyl (N-[3-methyl-1-(2- thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(XXXVI)

Morpheridine;

(XXXVII)

MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

(XXXVIII)

Noracymethadol;

(XXXIX)

Norlevorphanol;

(XL)

Normethadone;

(XLI)

Norpipanone;

(XLII)

Para-fluorofentanyl (N-(4-fluorophenyl)-N- [1-(2-phenethyl) -4-piperidinyl]-propanamide);

(XLIII)

PEPAP (1-(-2-phenethyl)-4-phenyl- 4-acetoxypiperidine);

(XLIV)

Phenadoxone;

(XLV)

Phenampromide;

(XLVI)

Phenomorphan;

(XLVII)

Phenoperidine;

(XLVIII)

Piritramide;

(XLIX)

Proheptazine;

(L)

Properidine;

(LI)

Propiram;

(LII)

Racemoramide;

(LIII)

Thiofentanyl (N-phenyl-N-[1-(2- thienyl) ethyl-4-piperidinyl]-propanamide);

(LIV)

Tilidine;

(LV)

Trimeperidine.

(b)

Any of the following opium derivatives, including their salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:

(I)

Acetorphine;

(II)

Acetyldihydrocodeine;

(III)

Benzylmorphine;

(IV)

Codeine methylbromide;

(V)

Codeine-N-Oxide;

(VI)

Cyprenorphine;

(VII)

Desomorphine;

(VIII)

Dihydromorphine;

(IX)

Drotebanol;

(X)

Etorphine, except hydrochloride salt;

(XI)

Heroin;

(XII)

Hydromorphinol;

(XIII)

Methyldesorphine;

(XIV)

Methyldihydromorphine;

(XV)

Morphine methylbromide;

(XVI)

Morphine methylsulfonate;

(XVII)

Morphine-N-Oxide;

(XVIII)

Myrophine;

(XIX)

Nicocodeine;

(XX)

Nicomorphine;

(XXI)

Normorphine;

(XXII)

Pholcodine;

(XXIII)

Thebacon.

(c)

Any material, compound, mixture, or preparation containing any quantity of the following hallucinogenic substances, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:

(I)

4-bromo-2, 5-dimethoxy-amphetamine (Some trade or other names: 4-bromo-2, 5-dimethoxy-alpha- methylphenethylamine; 4-bromo-2, 5-DMA.);

(II)

2,5-dimethoxyamphetamine (Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.);

(II.5)

2,5-Dimethoxy-4-ethylamphetamine (DOET);

(III)

4-methoxyamphetamine (Some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine, PMA.);

(IV)

5-methoxy-3,4-methylenedioxy amphetamine;

(IV.5)

5-methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT);

(V)

4-methyl-2,5-dimethoxy-amphetamine (Some trade and other names: 4-methyl-2,5-dimethoxy-alpha- methylphenethylamine; DOM; and STP.);

(VI)

3,4-methylenedioxy amphetamine;

(VII)

3,4-methylenedioxymethamphetamine (MDMA); except that 3,4-methylenedioxymethamphetamine (MDMA) does not include a prescription drug product containing 3,4-methylenedioxymethamphetamine (MDMA) approved by the federal food and drug administration and placed on a schedule of the federal “Controlled Substances Act”, 21 U.S.C. sec. 801 et seq., as amended, other than schedule I, or has been exempted from one or more provisions of such act, and that is intended for prescribed use and dispensed by a pharmacy or prescription drug outlet registered by the state of Colorado and only possessed by a person authorized to possess a controlled substance pursuant to section 18-18-302. Any such drug product containing MDMA that is approved by the federal food and drug administration must be controlled in Colorado in the same manner as required by any federal control designation pursuant to the federal “Controlled Substances Act”, or any exemption from one or more provisions of that act, and subject to the provisions set forth in part 1 of article 280 of title 12 and part 3 of this article 18. Nothing in this section exempts a person from any violation of part 4 of this article 18.

(VIII)

3,4,5-trimethoxy amphetamine;

(VIII.5)

Alpha-methyltryptamine (AMT);

(IX)

Bufotenine (Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2- dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.);

(X)

Diethyltryptamine (Some trade or other names: N,N-Diethyltryptamine; DET.);

(XI)

Dimethyltryptamine (Some trade or other names: DMT.);

(XII)

Ibogaine (Some trade and other names: (7-Ethyl-6,6B,7,8,9,10,12,13-octahydro-2- methoxy-6,9-methano-5H-pyrido [1’, 2’:1,2] azepine [5,4- b] indole; Tabernanthe iboga.);

(XIII)

Lysergic acid diethylamide;

(XIV)

Mescaline;

(XV)

Parahexyl (Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.);

(XVI)

Peyote (Meaning all parts of the plant classified botanically as Lophophora williamsii Lemaire, whether growing or not, its seeds, any extract from any part of the plant, and every compound, salt, derivative, mixture, or preparation of the plant, or its seeds or extracts);

(XVII)

N-ethyl MDA;

(XVIII)

N-ethyl-3-piperidyl benzilate;

(XIX)

N-hydroxy MDA;

(XX)

N-methyl-3-piperidyl benzilate;

(XXI)

Psilocybin;

(XXII)

Psilocyn;

(XXIII)

Tetrahydrocannabinols;

(XXIV)

Ethylamine analog of phencyclidine (Some trade or other names: N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexl) ethylamine, cyclohexamine, PCE.);

(XXV)

Pyrrolidine analog of phencyclidine (Some trade or other names: 1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP.);

(XXVI)

Thiophene analog of phencyclidine (Some trade or other names: 1-]1-(2-thienyl)-cyclohexyl- piperidine, 2-thienyl analog of phencyclidine, TPCP, TCP.);

(XXVII)

TCPy.

(d)

Any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:

(I)

Mecloqualone;

(II)

Methaqualone.

(e)

Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:

(I)

Repealed.

(II)

Fenethylline;

(III)

Methcathinone;

(IV)

N-ethylamphetamine;

(V)

(
+
) Cis-4-methylaminorex;

(VI)

N,N-dimethylamphetamine.

(f)

Any material, compound, mixture, or preparation containing any quantity of gamma hydroxybutyrate [GHB], including its salts, isomers, and salts of isomers.

(g)

Any material, compound, mixture, or preparation which is a controlled substance analog, the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in this subsection (2) or that was specifically designed to produce an effect substantially similar to or greater than the effect of a controlled substance listed in this subsection (2), all or part of which is intended for human consumption.

(h)

Any material, compound, mixture, or preparation containing any quantity of N-benzylpiperazine (BZP), including its salts, isomers, and salts of isomers.

Source: Section 18-18-203 — Schedule I, https://leg.­colorado.­gov/sites/default/files/images/olls/crs2023-title-18.­pdf (accessed Oct. 20, 2023).

18‑18‑101
Short title
18‑18‑102
Definitions
18‑18‑103
Special definition - board
18‑18‑201
Authority to control
18‑18‑202
Nomenclature
18‑18‑203
Schedule I
18‑18‑204
Schedule II
18‑18‑205
Schedule III
18‑18‑206
Schedule IV - repeal
18‑18‑207
Schedule V
18‑18‑301
Rules
18‑18‑302
Registration requirements - definitions
18‑18‑303
Registration
18‑18‑304
Suspension or revocation of registration
18‑18‑305
Order to show cause
18‑18‑306
Records of registrants
18‑18‑307
Order forms
18‑18‑308
Prescriptions
18‑18‑309
Diversion prevention and control
18‑18‑401
Legislative declaration
18‑18‑402
Definitions - terms used
18‑18‑403
Additional definition
18‑18‑403.5
Unlawful possession of a controlled substance - notice to revisor of statutes - repeal
18‑18‑404
Unlawful use of a controlled substance
18‑18‑405
Unlawful distribution, manufacturing, dispensing, or sale
18‑18‑406
Offenses relating to marijuana and marijuana concentrate - definitions
18‑18‑406.1
Unlawful use or possession of synthetic cannabinoids or salvia divinorum
18‑18‑406.2
Unlawful distribution, manufacturing, dispensing, sale, or cultivation of synthetic cannabinoids or salvia divinorum
18‑18‑406.3
Medical use of marijuana by persons diagnosed with debilitating medical conditions - unlawful acts - penalty - medical marijuana program cash fund
18‑18‑406.4
Unlawful advertising of marijuana - exception
18‑18‑406.5
Unlawful use of marijuana in a detention facility
18‑18‑406.6
Extraction of marijuana concentrate - definitions
18‑18‑406.9
Unlawful distribution or purchase of dextromethorphan - penalty - preemption - definitions
18‑18‑407
Special offender - definitions
18‑18‑409
Reduction or suspension of sentence for providing substantial assistance
18‑18‑410
Declaration of class 1 public nuisance
18‑18‑411
Keeping, maintaining, controlling, renting, or making available property for unlawful distribution or manufacture of controlled substances
18‑18‑412
Abusing toxic vapors - prohibited
18‑18‑412.5
Unlawful possession of materials to make methamphetamine and amphetamine - penalty
18‑18‑412.7
Sale or distribution of materials to manufacture controlled substances
18‑18‑412.8
Retail sale of methamphetamine precursor drugs - unlawful acts - penalty
18‑18‑413
Authorized possession of controlled substances
18‑18‑414
Unlawful acts - licenses - penalties
18‑18‑415
Fraud and deceit
18‑18‑416
Controlled substances - inducing consumption by fraudulent means
18‑18‑417
Notice of conviction
18‑18‑418
Exemptions
18‑18‑419
Imitation and counterfeit controlled substances act
18‑18‑420
Imitation controlled substances - definitions
18‑18‑421
Imitation controlled substances - determination - considerations
18‑18‑422
Imitation controlled substances - violations - penalties
18‑18‑423
Counterfeit substances prohibited - penalty
18‑18‑424
Imitation controlled substances - exceptions
18‑18‑425
Drug paraphernalia - legislative declaration
18‑18‑426
Drug paraphernalia - definitions
18‑18‑427
Drug paraphernalia - determination - considerations
18‑18‑428
Possession of drug paraphernalia - penalty
18‑18‑429
Manufacture, sale, or delivery of drug paraphernalia - penalty
18‑18‑430
Advertisement of drug paraphernalia - penalty
18‑18‑430.5
Drug paraphernalia - exemption
18‑18‑431
Defenses
18‑18‑432
Drug offender public service and rehabilitation program - definitions
18‑18‑433
Constitutional provisions
18‑18‑434
Offenses relating to natural medicine and natural medicine product - definitions
18‑18‑501
Administrative inspections and warrants
18‑18‑502
Injunctions
18‑18‑503
Cooperative arrangements and confidentiality
18‑18‑504
Pleadings - presumptions - liabilities
18‑18‑505
Judicial review
18‑18‑506
Education and research
18‑18‑601
Pending proceedings - applicability
18‑18‑602
Continuation of rules - application to existing relationships
18‑18‑603
Statutes of limitations
18‑18‑604
Uniformity of interpretation
18‑18‑605
Severability
18‑18‑606
Drug case data collection
18‑18‑607
Safe stations - disposal of controlled substances - medical evaluation - definition
Green check means up to date. Up to date

Current through Fall 2024

§ 18-18-203’s source at colorado​.gov